FLT201: Initial Clinical Data

Creating better gene therapies for chronic debilitating diseases Potential first- and best-in-class lead program Highly differentiated gene therapy candidate FLT201 for Gaucher disease type 1 in first-in-human clinical trial Extending innovation into Parkinson's disease Lead research program leveraging our novel GCase variant for GBA1- linked Parkinson's disease Fol - Compelling initial clinical data Robust enzyme activity and favorable safety and tolerability in first two patients treated with FLT201 Experienced management team Seasoned leaders with the experience and expertise to drive progress and execution Our approach is to optimize all components of our product candidates to unlock the true potential of gene therapy FREELNE 3

View entire presentation